Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06154447 · ClinicalTrials.gov registry record · Phase 1
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
A Phase 1 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 255
- Enrollment target
- 11
- Study locations
NCT06154447: Recruiting Phase 1 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06154447 is a Phase 1 study of Cystic Fibrosis that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 255 participants, above the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (43% higher). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06154447, a Phase 1 study of Cystic Fibrosis, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 255 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Itraconazole
- DRUG VX-828
- DRUG Tezacaftor
Study Locations (11)
Florida
- Joe DiMaggio Cycstic Fibrosis & Pulmonary Center - Hollywood
- Central Florida Pulmonary Group, P.A. - Orlando
Kansas
- Altasciences Clinical Kansas - Overland Park
Kentucky
- Kentucky Children's Hospital - Lexington
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- University of Minnesota -Pulmonology - Minneapolis
New York
- New York Medical College - Hawthorne
Ohio
- ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC - Toledo
Texas
- Cook Children's Pulmonology - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2026-04-23 |
| Phase | Phase 1 |
What NCT06154447 shows while recruiting
NCT06154447 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06154447 lists 11 locations in 10 states (Florida, Kansas, Kentucky).
Frequently Asked Questions
What is clinical trial NCT06154447 about?
NCT06154447 is a clinical study titled "Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis". The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic ...
What is the current status of trial NCT06154447?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 255 participants. The study started on 2023-12-12. Estimated completion is 2026-04-23.
What conditions does trial NCT06154447 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT06154447?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Itraconazole (DRUG), VX-828 (DRUG), Tezacaftor (DRUG).
Who is sponsoring clinical trial NCT06154447?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06154447 being conducted?
This trial has 11 study locations across Florida, Kansas, Kentucky, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06154447's enrollment target sits among peer trials
255 27th of 169 higher than 143 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI